|
Volumn 357, Issue 9269, 2001, Pages 1704-1706
|
Antioxidant strategy for cardiovascular disease [1] (multiple letters)
e
Canynge Hall
*
(United Kingdom)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACETYLSALICYLIC ACID;
ALPHA TOCOPHEROL;
ANTIOXIDANT;
BETA CAROTENE;
ADULT;
ANTIOXIDANT ACTIVITY;
BIOAVAILABILITY;
BLEEDING;
CARDIOVASCULAR DISEASE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CORONARY ARTERY DISEASE;
DOSE RESPONSE;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
EPIDEMIOLOGICAL DATA;
FEMALE;
FOLLOW UP;
GASTROINTESTINAL ABSORPTION;
HUMAN;
LETTER;
LIPID PEROXIDATION;
LONG TERM CARE;
MALE;
META ANALYSIS;
MORTALITY;
NORMAL HUMAN;
OXIDATIVE STRESS;
POPULATION RISK;
PRIORITY JOURNAL;
PROPHYLAXIS;
RISK FACTOR;
THROMBOSIS;
TREATMENT OUTCOME;
NOTE;
RANDOMIZED CONTROLLED TRIAL;
CAUSE OF DEATH;
COMPARATIVE STUDY;
STATISTICAL ANALYSIS;
SURVIVAL RATE;
ANTIOXIDANTS;
ASPIRIN;
CARDIOVASCULAR DISEASES;
FOLLOW-UP STUDIES;
HUMANS;
RANDOMIZED CONTROLLED TRIALS;
RISK FACTORS;
TREATMENT OUTCOME;
VITAMIN E;
CAUSE OF DEATH;
DATA INTERPRETATION, STATISTICAL;
SURVIVAL RATE;
|
EID: 0035954018
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(00)04834-0 Document Type: Letter |
Times cited : (19)
|
References (0)
|